bluuebunny/crossref_metadata_2025_split huggingface dataset:
1049 – Correlates Of Postpartum Depressive Symptomatology
Authors: Roque C. , Pereira A.T. , Marques M. , Soares M.J. , Maia B. , Bos S. , Azevedo M.H. , Valente J. , Nogueira V. , Madeira N. , Macedo A. 
Published: July 2013

IntroductionPostpartum depressive symptomatology is highly prevalent and has negative impact in the entire family.ObjectiveTo identify correlates of postpartum depressive symptomatology.Methods201 3-months postpartum women completed the Portuguese versions of Postpartum Depression Screening Scale/PDSS, Profile of Mood States, Difficult Infant Temperament Questionnaire/DITQ, Multidimensional Perfectionism Scale and questions on sociodemographic variables (marital status, work status, educational level, parity), Lifetime history of insomnia/LTHD, Lifetime history of depressive symptomatology /LTHDS, Current insomnia, Sleep needs, Health perception/HP, Stress perception/SP, Perceived social support/PSS, Quality of life/QOL, Health problem/complication postpartum, Sensibility to hormonal fluctuations, Type of delivery and Type of feeding.ResultsTotal PDSS significantly correlated with LTHDS (rs=.35), LHI (rs=.22), Current insomnia (rs=.37), SP (rs=39), PSS (rs=.25), Perceived QOL (rs=.31), Health perception (rs=.28), Health problem or complication in the postpartum (rs=.16), Negative Affect/NA (r=.59), Positive Affect/PA (r=-.67), Conditional Acceptance/CA(r=.29) and DIT (r=.40) (all p< .01). Mean comparisons revealed that women with vs. without LHDS, with vs. without LTHI, good sleepers vs. with insomnia syndrome, high vs. low SP, bad/very bad vs. good/very good QOL, bad/very bad vs. good very good HP, high (< M+1DP) vs. low (>M-1DP) DIT, CA, NA and low vs. high PA had significantly higher mean scores in AI (all p< .01). Linear regression model composed of all correlated variables explained 53.9% of depressive symptomatology variance and showed that NA, PA, DIT and HP are significant (p< .05) predictors of AI.ConclusionThese results are in line with previous findings and contribute to the progress on this topic.
1053 – In Vitro Receptor-binding Profile Of Lurasidone And Other Commonly-used Antipsychotics
Authors: Werner P. , Ishiyama T. , Loebel A. , Cucchiaro J. , Horisawa T. , Tokuda K. , Ogasa M. , Ishibashi T. , Stahl S.M. 
Published: July 2013

IntroductionAtypical antipsychotics bind to multiple receptor types and subtypes. Improved outcomes in schizophrenia are linked to activity at D2 and serotonin receptors 5-HT7, 5-HT2A and 5-HT1A.ObjectivesTo characterize the receptor-binding profile of lurasidone and other antipsychotics.AimsTo compare receptor-binding profiles of antipsychotics.MethodsReplicated, side-by-side receptor-binding assays used human recombinant receptors (for 5-HT7, α2A, and α2C) or membrane-fractions of animal CNS tissue. Affinities were determined via Hill plot analysis for IC50values; Ki values were determined using Ki=IC50/(1+ S/Kd) (S=concentration of competing radioligand, Kd=dissociation constant).ResultsLurasidone displayed potent binding and full antagonism at dopamine D2(Ki, 1.68nM) and serotonin 5-HT2A(Ki, 2.03nM) receptors (the highest D2affinity of all tested agents). Lurasidone's dopamine binding was selective for D2receptors. Unlike other antipsychotics tested, lurasidone had very high affinity and full antagonism at serotonin 5-HT7(Ki, 0.49nM), and nanomolar affinity (Ki=6.75nM) with weak-moderate partial agonism at serotonin 5-HT1Areceptors., Lurasidone showed higher affinity for 5-HT7, 5-HT2A, and 5-HT1Areceptors relative to D2receptor-binding than other agents. Lurasidone displayed moderate affinity for α2C adrenoceptors (Ki, 10.8nM); moderate-weak affinity for α1adrenoceptors (Ki, 48nM); and minimal or unappreciable affinity for receptors associated with undesirable effects (5-HT2C [Ki, 415nM], histamine H1[IC50>1000nM] and muscarinic [cholinergic] M1[IC50>1000nM] receptors).ConclusionsThe unique pharmacological profile of lurasidone is consistent with observed antipsychotic efficacy, low-tomoderate likelihood of EPS, low weight-gain potential, and possible mood, anxiety, and cognitive benefits.
1055 – Effect Of Lurasidone On Weight And Metabolic Parameters: a Comprehensive Analysis Of Short- And Long-term Trials In Schizophrenia
Authors: Pikalov A. , Cucchiaro J. , Ogasa M. , Silva R. , Hsu J. , Xu J. , Loebel A. 
Published: July 2013

IntroductionPatients with schizophrenia are at high risk for diabetes, dyslipidemia, hypertension, and obesity, which can be exacerbated by some atypical antipsychotics.ObjectivesTo evaluate the effect of lurasidone on weight and metabolic parameters.AimsTo establish the cardiometabolic safety of lurasidone.MethodsShort-term data were pooled from seven, double-blind, 6-week studies of subjects with acute exacerbation of schizophrenia treated with lurasidone 20-160 mg/day (N=1508); haloperidol 10 mg/day (N=72); olanzapine 15 mg/day (N=122); risperidone 4 mg/day (N=65); quetiapine XR 600 mg/day (N=119) or placebo (N=708). Long-term data (6-22 months) were pooled from patients treated with lurasidone 40-120 mg/day (flexibly dosed).ResultsProportions of patients experiencing ≥7% weight gain during short-term treatment were: lurasidone 4.8%, haloperidol 4.2%, olanzapine 34.4%, risperidone 6.2%, quetiapine XR 15.3%, and placebo 3.3%. Median lipid changes were: triglycerides (mg/dL), lurasidone -4.0, haloperidol -3.0, olanzapine +25.0, risperidone +4.0, quetiapine XR +9.5, and placebo -6.0; total cholesterol (mg/dL), lurasidone -5.0, haloperidol -8.0, olanzapine +9.0, risperidone +6.5, quetiapine XR +6.0, and placebo -5.0; trends were similar for LDL. Median changes in glucose (mg/dL) were similar for lurasidone (0.0) and placebo (0.0), and higher for haloperidol (+2.0), olanzapine (+4.0), risperidone (+3.0), and quetiapine XR (+3.0). Minimal-to-no changes in HbA1c were observed. With long-term lurasidone treatment, mean weight change after 12-month exposure was -0.73 kg and median metabolic changes were: -2.0 mg/dL for total cholesterol and -5.0 mg/dL for triglycerides.ConclusionsShort- and long-term treatment with lurasidone showed minimal changes in weight and decrease in mean total and LDL cholesterol and triglycerides.
1065 – Relationship Between Insight, Psychopathology And Executive Functions In a Sample Of Forensic Patients
Authors: Martins V. , Pimenta S. , Massano R. , Martins I. , Canhão A. 
Published: July 2013

IntroductionThe study of the relationship between insight, psychopathology and executive functions has revealed contradictory results, which seems to demonstrate the complex and multidisciplinary nature of insight. Several studies in psychotic patients confirmed the association between lower insight and poor prognosis, emphasizing the impact of poor adherence to treatment in greater symptom severity and greater likelihood of aggressive behavior.ObjectivesTo study the relationship between insight, psychopathology and executive functions. Analyze the association between these variables and the type of crime committed in a sample of forensic patients.MethodsThe sample is comprised by patients hospitalized for more than 6 months in the Department of Forensic Psychiatry of the Centro Hospitalar e Universitário de Coimbra, diagnosed as measured by DSM-IV-TR, in the category “Schizophrenia and other Psychotic Disorders”. Of these, we excluded those that according to DSM-IV-TR had a diagnosis of “Mental Retardation” (IQ as measured by WASI - Wechsler Abbreviated Scale of Intelligence) or “Substance Dependence”. Patients were evaluated using PANSS (Positive and Negative Syndrome Scale), SUMD (Scale to Assess Unawareness of Mental Disorders) and TMT (Trail Making Test). Biographical data, type of crime that led to the hospitalization and the security measure applied, was gathered through the review of patient's clinical files.Results and conclusionsData will be analyzed using the Statistical Package for Social Sciences (SPSS - 19th version) and the results will be interpreted according to the current literature.
1067 – Effect Of Calreticulin On Hippocampus Of Post-traumatic Stress Disorder Rats
Authors: Liu H. , Han F. , Shi Y. 
Published: July 2013

ObjectiveTo detect molecular chaperone calreticulin(CRT) expression on the hippocampus in the rat model of post-traumatic stress disorder(PTSD), and discuss the regulation of CRT on Ca2+ in hippocampus of PTSD rats, further provide the experiment basis for pathogenesis of memory anomaly in PTSD rats.MethodsThe single-prolonged stress(SPS) is one of the animal models was used to set up the rat PTSD models. Male Wistar rats were randomly divided into 1, 4, 7 days groups after exposure to SPS and a normal control group. The expression of CRT was detected by using immunohistochemistry, Western blotting and RT-PCR. The intracellular free calcium was examined by fluorescence spectrophotometer.ResultsThe expression of CRT in the hippocampus obviously increased after SPS stimulation, and reached the peak at SPS 4d. The intracellular free calcium level in the hippocampus obviously increased, and reached the peak at SPS 1d, then gradually decreased.ConclusionsPTSD caused endoplasmic reticulum stress(ERS), calcium overload, up-regulated expression of CRT, activation of unfolded protein response(UPR), which maybe result in cell apoptosis and maybe the pathogenesis basis on memory anomaly in PTSD rats.
1075 – Directions For Community Psychiatry In The u.s.: a Pilot Qualitative Study
Authors: Bouloudnine R. , Rowe M. 
Published: July 2013

Community psychiatry is at a crossroads in the U.S. This crisis can be characterized by the discipline's relationship to: tension between social and biological psychiatry; and the Recovery Movement. Confronted with the strong presence of biological psychiatry, with social conditions that are not a core focus of their training, and with a strong push from patients, advocates, and some policy makers to create recovery-oriented care that, often, seems to minimize the importance of psychiatrists, the question - “What is community psychiatry in the U.S. - must be posed.MethodThis research, conducted at Yale University with IRB approval, involved 12 in-depth qualitative interviews with community psychiatrists at a public mental health center. The main interview question - “What is a psychiatrist? - was followed by questions involving the themes noted above.ResultFor the psychiatrists, psychiatry seems deeply embedded in medicine. If the biological model has been able to improve some parts of psychiatric practice, many psychiatrists will identify the limits of this model and feel frustration from its tendency to marginalize their role into one of medication management.ConclusionRegarding this lack of knowledge and understanding of mental illnesses, regarding the crisis that the health system is undergoing, it seems necessary to go above a simple definition of a psychiatrist as someone with skills for treating mental illness. With which skills can psychiatrists improve symptoms, the life context that contributes to patients’ symptoms, and the mental health delivery system that often misses people's needs? Or going further, how can psychiatrists best advocate for their clients?
1083 – Withdrawal From Benzodiapezines In Spa Treatment
Authors: Dubois O. 
Published: July 2013

The recent results stemming from the STOP-TAG [Dubois O, et al.; Balneotherapy versus paroxetine in the treatment of generalized anxiety disorder, Complementary Therapies in Medicine (fév 2010) 18, 1-7] study have shown the way to demonstrating the considerable efficacy of psychiatric spa therapy compared to a reference treatment (Paroxetine) in generalized anxiety disorders. The study carried out on 237 patients has clearly indicated the impact of balneotherapy in this indication with indisputable evidence.The questionable problem of withdrawal from benzodiapezines is a well-known issue throughout European countries, particularly in France. For instance, 11.2% of the French are regular benzodiapezine consumers and 70% of the prescriptions are made out to them for as long as 5 years!No therapy has ever actually shown a satisfactory efficacy to treat the problem. The given elements converge to propose programmes of a psycho-educative kind.As a result, this has led us to the conclusion that a protocol, which would be set up and supervised by university academics, ensured by trained psychologists with medical withdrawal follow-up to be carried out within the spa therapy, could well allow withdrawal from this medication. The spa therapy, through its proven anxiolytic activity, is able to favour the substituting of treatment by benzodiapezine, and as a result would make withdrawal easier.We propose here to set out the psycho-educative protocol with the support of an experiment on 73 patients, carried out in 2010 and 2011 in France together with the results of this study.
1086 – Barriers To Somatic Health Care In Psychiatric Inpatient Wards
Authors: Okkels N. , Thygesen N.B. , Jensen B. , Wendelboe M.H. , Munk-Joergensen P. 
Published: July 2013

IntroductionCardiometabolic diseases are under-diagnosed and under-treated in psychiatric inpatients. A common solution is implementation of screening guidelines. However, we often forget to ask the essential question: Why were our patients underdiagnosed in the first place?ObjectiveTo identify causes of under-diagnosing and under-treatment in the context of local clinical practices.MethodAll consecutive admissions (n=63) over 93 days were screened for hypertension, diabetes, dyslipidemias and abdominal obesity. Patients identified with both (a) undiagnosed and untreated disease and (b) admission on a separate occasion within the previous two years to the ward in question, were selected for a retrospective patient file review. These patients (n=32) had their medical records scrutinized for information on how each cardiometabolic measure was assessed at previous admission.ResultsRelevant examination were performed in 38% of cases and test results were abnormal for 54% of these. Abnormal test results were evaluated in 14% of cases and none of the evaluated results were acted upon.ConclusionRigorous examination and testing of patients is only of value if clinicians have the essential knowledge to interpret the results and feel responsibility to do so. These barriers must be broken down before implementing screening guidelines in routine clinical practice.
1099 – Hospital Care For Alcohol-dependent Patients: Attentional Bias Measured With The French Version Of The “alcohol Stroop Test”
Authors: Flaudias V. , Brousse G. , Llorca P.-M. , Planche F. , Brun J. , De Chazeron I. 
Published: July 2013

AimsPrevious studies have shown in alcohol dependence patients an attentional bias (AB) under related substance cues which can be a factor of relapse. This AB can be evaluated by the “Alcohol Stroop Test” (AST). The AST is a modified Stroop task while participant have to name the color of the word. This word could be alcohol-related word or a neutral word. AB is the response time's difference between alcohol-related words and neutral words. The goal of the current study was to examine the relation between withdrawal hospitalization and AB.MethodsIndividuals with alcohol-dependence disorders (DSM IV) and admitted for withdrawal in addictology unit of CHU Clermont-Ferrand (n=42) and participant with no alcohol or psychiatric disorder recruited from colleagues and friends from the staff performed the AST (n=16) (‘Control Group’) were recruited. For inpatients, one group performed the AST in admission (n=19) (‘Admission Group’), and another group immediately before discharge (n=23) (‘Discharge Group’).ResultsResults show an AB only for patients saw at admission (t(18) =2.12; p< .05). Moreover, we observe that the AB in ‘Admission Group’ (M=34 ms, SD= 70.06) is greater than the AB in ‘Control group’ AB (M = 23 ms, SD = 93.42), itself greater than the AB in ‘Discharge Group’ (M = -12 ms, SD=93.55), (t(55) = -1.71; p =.09).ConclusionsAlthough, results are preliminary, the present study provides evidence for the evolution of AB during alcohol addiction treatment and for the value of incorporated method to improve AB during detoxification cure.
1103 – Obesity, Psychopathology And Neuropsychology: Clinical And Therapeutic Considerations
Authors: Paoli R.A. , Zugno E. , Caletti E. , Paganelli L. , Prunas C. , Ostinelli E. , Altamura A.C. 
Published: July 2013

IntroductionExperimental evidence indicates that patients with severe mental illness such as schizophrenia or mood disorders have a higher incidence of overweight and obesity (Daumit et al., 2003).ObjectivesThis review describes the neuropsychological functioning and therapeutical approaches (psychotherapeutic, pharmacological, surgical) in obese patients with psychiatric disorders.AimsTo provide suggestions for good clinical practice in obese subjects with psychopathology, based on data found in the literature.MethodsMEDLINE and PubMed databases (1962-2012) were searched for English-language articles.ResultsMost of the literature says that the best treatment for these patients should use an integrated approach, starting from an assessment of the psychological and cognitive resources to set up a more effective and personalized therapeutic path.ConclusionsObese patients who have psychiatric disorders represent a population that requires specific treatment measures; in fact, the development, the maintenance and the outcome of the problem of weight are influenced not only by physical and life style factors, but also by specific factors related to psychopathology, neuropsycology, and side effects of certain drugs.
1107 – Esense 1 - Randomised Controlled 6-month Study Of As-needed Nalmefene: Subgroup Analysis Of Alcohol Dependent Patients With High Drinking Risk Level
Authors: van den Brink W. , Aubin H.-J. , Bladström A. , Torup L. , Mann K. , Gual A. 
Published: July 2013

IntroductionWe describe the efficacy and safety of as-needed use of nalmefene in the subgroup of patients with a high drinking risk level (DRL; men:>60g/day; women:>40g/day); i.e. a group of patients with a great unmet medical need for treatment.ObjectivesTo evaluate the 6 month efficacy and safety of as-needed use of nalmefene 18mg versus placebo in a subgroup of alcohol-dependent patients with high DRL from a randomised controlled trial [NCT00811720].MethodsAll patients received a motivational and adherence-enhancing intervention (BRENDA) in combination with either nalmefene or placebo. Number of heavy drinking days (HDDs) and total alcohol consumption (TAC) were measured using the Timeline Follow-back method. Additionally, data on clinical improvement, liver function and safety were collected throughout the study.ResultsThe study population consisted of 350 patients: placebo N=170; nalmefene N=180 (mean age 51.9±9.4 years; 63% men; mean HDDs: 23±5.7/month; mean TAC: 101±41.7g/day). Mean number of HDDs decreased to 11 days/month and mean TAC decreased to 44g/day at month 6 in the nalmefene group. There was a superior effect of nalmefene compared to placebo in reducing the number of HDDs (-3.7 [95% CI: -5.9;-1.5];p=0.0010) and TAC (-18.3 [-26.9;-9.7];p< 0.0001) at month 6. Improvements in clinical status and liver parameters were greater in the nalmefene group compared to the placebo group (p< 0.05). Adverse events and adverse events leading to dropout were more common with nalmefene than placebo.ConclusionsAs-needed nalmefene was efficacious in reducing alcohol consumption in patients with high risk for alcoholrelated harm.
1108 – Esense 2 - Randomised Controlled 6-month Study Of As-needed Nalmefene: Subgroup Analysis Of Alcohol Dependent Patients With High Drinking Risk Level
Authors: van den Brink W. , Aubin H.-J. , Sørensen P. , Torup L. , Mann K. , Gual A. 
Published: July 2013

IntroductionWe describe the efficacy and safety of as-needed use of nalmefene in the subgroup of patients with a high drinking risk level (DRL; men:>60g/day; women:>40g/day); i.e. a group of patients with a great unmet medical need for.ObjectivesTo evaluate the 6 month efficacy and safety of as-needed use of nalmefene 18mg versus placebo in a subgroup of alcohol-dependent patients with high DRL from a randomised controlled trial [NCT00812461].MethodsAll patients received a motivational and adherence-enhancing intervention (BRENDA) in combination with either nalmefene or placebo. Number of heavy drinking days (HDDs) and total alcohol consumption (TAC) were measured using the Timeline Follow-back method. Additionally, data on clinical improvement, liver function and safety were collected throughout the study.ResultsThe study population consisted of 317 patients: placebo N=162; nalmefene N=155 (mean age 44.8±10.3 years; 69% men; mean HDDs: 22±6.2/month; mean TAC 111±47.9g/day). Mean number of HDDs decreased to 10 days/month and mean TAC decreased to 43g/day at month 6 in the nalmefene group. There was a superior effect of nalmefene compared to placebo in reducing the number of HDDs (-2.7 [95% CI: -5.0;-0.3];p=0.0253) and TAC -10.3 [-20.2;-0.5];p=0.0404). Improvements in clinical status and alanine amino transferase were greater in the nalmefene group compared to the placebo group (p< 0.05). Adverse events were more common with nalmefene; incidence of adverse events leading to dropout was at the placebo level.ConclusionsAs-needed nalmefene was efficacious in reducing alcohol consumption in patients with high risk for alcoholrelated harm.
1119 – The Impact Of Soluble Interleukin-2 Receptor As a Biomarker Of Delirium
Authors: Baranyi A. , Rothenhäusler H.-B. 
Published: July 2013

IntroductionMuch speaks in favour of searches for biomarkers that might help to predict the emergence of delirium. Advance warning of the threats of this condition could potentially reduce significant morbidity, mortality, and costs of hospitalising patients.AimsOur prospective study investigates for the first time the impact of soluble interleukin-2 receptor (sIL-2R) as a biomarker of delirium after cardiac surgery with cardiopulmonary bypass (CPB).Methods34 patients who underwent elective CPB at the Department of Cardiac Surgery, Ludwig-Maximilians-University of Munich, Germany, were enrolled. During the ICU stay and after discharge from the ICU, the delirious state was evaluated daily using the Delirium-Rating-Scale (DRS) by P. T. Trzepacz. sIL-2R was assayed before CPB, 24 h postoperatively and on the day before discharge.ResultsAfter the CPB, 11 patients (32.4%) developed delirium. During the study period the sIL-2R level decreased at 24h postoperatively and increased afterwards. In the subgroup of patients with a postoperative delirious state longer than 24 hours the sIL-2R level is statistically significantly elevated 24h postoperatively in comparison with CPB-patients without a postoperative delirious state. Furthermore, as shown by a Spearman's rank correlation, CPB patients with higher Delirium-Rating-Scale scores 72h, 96h and 120h postoperatively had significant higher sIL-2R levels 24h postoperatively.ConclusionsHigh levels of sIL-2R appear to be a useful biomarker to identify patients with high risk of delirious state.